X
CDLX icon

Xponance’s Cardlytics CDLX Stock Holding History

Xponance’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-175
Closed -$222K – 1191
2021
Q2 		$222K Buy
+175
New +$197K ﹤0.01% 1146

Other funds holding CDLX

CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
ACM
Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return
KGAMU
KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Xponance's CDLX Position: Q3 2021 in Review

Xponance sold out of Cardlytics (CDLX) in Q3 2021, closing a stake of 175 shares — an estimated $222K sold.

Xponance first reported a position in CDLX in Q2 2021 and held it in 1 quarter. The position peaked at $222K in Q2 2021. 164 funds tracked by Wall St. Rank hold CDLX as of Q3 2021.

  • Xponance reported no remaining Cardlytics position as of Q3 2021 after selling out during the quarter.
  • Xponance sold 175 Cardlytics shares in Q3 2021, an estimated $222K.
  • Xponance first reported a position in Cardlytics in Q2 2021 and held it in 1 quarter.
  • Xponance's Cardlytics position peaked at $222K in Q2 2021.
  • 164 funds tracked by Wall St. Rank held Cardlytics as of Q3 2021.

Based on Xponance's 13F filing for Q3 2021, filed 5 Nov 2021.